Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D3 as host directed therapy by Rekha, Rokeya Sultana et al.
RESEARCH ARTICLE Open Access
Immune responses in the treatment of
drug-sensitive pulmonary tuberculosis
with phenylbutyrate and vitamin D3 as
host directed therapy
Rokeya Sultana Rekha1,2†, Akhirunnesa Mily1,2†, Tajnin Sultana1, Ahsanul Haq1, Sultan Ahmed1,2,
S. M. Mostafa Kamal3, Annemarie van Schadewijk4, Pieter S. Hiemstra4, Gudmundur H. Gudmundsson5,
Birgitta Agerberth2† and Rubhana Raqib1*†
Abstract
Background: We have previously shown that 8 weeks’ treatment with phenylbutyrate (PBA) (500mgx2/day) with or
without vitamin D3 (vitD3) (5000 IU/day) as host-directed therapy (HDT) accelerated clinical recovery, sputum culture
conversion and increased expression of cathelicidin LL-37 by immune cells in a randomized, placebo-controlled trial
in adults with pulmonary tuberculosis (TB). In this study we further aimed to examine whether HDT with PBA and
vitD3 promoted clinically beneficial immunomodulation to improve treatment outcomes in TB patients.
Methods: Cytokine concentration was measured in supernatants of peripheral blood mononuclear cells (PBMC) from
patients (n = 31/group). Endoplasmic reticulum stress-related genes (GADD34 and XBP1spl) and human beta-defensin-1
(HBD1) gene expression were studied in monocyte-derived-macrophages (MDM) (n = 18/group) from PBMC of
patients. Autophagy in MDM (n = 6/group) was evaluated using LC3 expression by confocal microscopy.
Results: A significant decline in the concentration of cytokines/chemokines was noted from week 0 to 8 in
the PBA-group [TNF-α (β = − 0.34, 95% CI = − 0.68, − 0.003; p = 0.04), CCL11 (β = − 0.19, 95% CI = − 0.36, − 0.03; p = 0.02)
and CCL5 (β = − 0.08, 95% CI = − 0.16, 0.002; p = 0.05)] and vitD3-group [(CCL11 (β = − 0.17, 95% CI = − 0.34, − 0.001; p
= 0.04), CXCL10 (β = − 0.38, 95% CI = − 0.77, 0.003; p = 0.05) and PDGF-β (β = − 0.16, 95% CI = − 0.31, 0.002; p = 0.05)]
compared to placebo. Both PBA- and vitD3-groups showed a decline in XBP1spl mRNA on week 8 (p < 0.03). All
treatment groups demonstrated increased LC3 expression in MDM compared to placebo over time (p < 0.037).
Conclusion: The use of PBA and vitD3 as adjunct therapy to standard TB treatment promoted favorable
immunomodulation to improve treatment outcomes.
Trials registration: This trial was retrospectively registered in clinicaltrials.gov, under identifier NCT01580007.
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Background
Tuberculosis remains among the top 10 leading causes of
death with global estimates of 10.4 million new cases and
1.4 million deaths in 2015 [1]. Control or exacerbation of
TB is dependent on host immune responses generated to
combat Mycobacterium tuberculosis (Mtb) infection [2–4].
Several studies have unravelled immunological pathways
that influence the outcome of Mtb infection which include
cytokine-mediated signalling among T cells, macrophages
and neutrophils, and phagocytes-mediated antimicrobial
processes [4–9]. Studying cytokine profiles in TB patients
has demonstrated its potential for use in diagnostic pur-
poses, monitoring of treatment efficacy and development
of novel treatment strategies [10–14]. Autophagy in
macrophages and intracellular lysosomal degradation are
important for killing of pathogens although Mtb has
evolved to escape elimination by blocking phagosomal
acidification and phagosome-lysosomal fusion [15–17].
Endoplasmic-reticulum (ER) stress response is triggered
by mycobacterial infection and plays a critical role in the
pathogenesis of TB [18].
The rise in antibiotic resistance among Mtb in the last
decade rekindled attention towards alternative chemother-
apies. Host-directed therapies (HDT) have emerged as a
promising avenue for adjunctive treatment with the aim to
modulate immune responses against the pathogen by
targeting clinically relevant host biological pathways. This
strategy would be beneficial in reducing the course of
antibiotic treatment, preventing the spread of
drug-resistant Mtb, and reducing inflammation in the lung
(reviewed in [19, 20]). Phenylbutyrate (PBA) is a licensed
drug indicated for the management of urea cycle disorders
[21]. Vitamin D3 (vitD3), a dietary supplement, has diverse
immune-modulatory properties. Our group has shown
that PBA and vitD3 have a strong synergistic effect on in-
duction of antimicrobial peptides (AMPs) in lung epithelial
cell lines, macrophages, and in healthy human immune
cells [22–24]. In a randomized clinical trial, we have shown
that PBA alone or combined with vitD3 is a promising
candidate for HDT in the treatment of drug sensitive pul-
monary TB by speeding up clinical recovery [25]. Treat-
ment with vitD3 or the combination with PBA accelerated
sputum culture conversion and enhanced expression of
LL-37, the human AMP of the cathelicidin family, by
immune cells. Moreover, PBA adjunctive therapy increased
macrophage-mediated killing of Mtb ex vivo compared to
placebo. Our in vitro study further showed that PBA can
induce autophagy in a LL-37 dependent pathway and pro-
motes intracellular killing of Mtb in human macrophages
[23]. PBA is known to reduce ER stress in cells and
thereby reduce inflammatory responses [26, 27]. We
hypothesized that the beneficial effects imparted by HDT
of PBA and vitD3 in TB patients may be mediated through
regulating expression of cytokines, chemokines and AMPs
by immune cells, augmentation of autophagic responses of
macrophages and reduction of chronic ER stress. Thus, in
a sub-group of TB patients, we evaluated the effect of
HDT on dynamics of cytokines and chemokines in culture
supernatants of PBMC, HBD1 and ER stress genes and
expression of LC3, an autophagy marker, in macrophages
from TB patients in response to the disease and clinical
improvement.
Methods
Patients, study design and interventions
For this study, we used materials collected during our
previously published clinical trial [25]. Briefly, 288 adult
patients with newly diagnosed sputum smear-positive
TB (18–55 years of age) were recruited from the
National Institute of the Diseases of the Chest and Hos-
pital (NIDCH) in Dhaka, Bangladesh. The study was
approved by the Research and Ethical Review Commit-
tees at icddr,b, an international health research institute
based in Bangladesh. The study was a double-blind,
placebo-controlled trial in which patients were random-
ized to the following adjunct therapy arms (72 × 4)
receiving oral doses of either: (1) placebo PBA and
placebo vitD3; or (2) 500 mg twice daily of PBA and
placebo vitD3; or (3) placebo PBA and 5000 IU of vitD3
(Cholecalciferol) once daily; or (4) PBA combined with
vitD3 (PBA + vitD3). In parallel, standard care of directly
observed therapy short-course (DOTS) regimen consist-
ing of isoniazid (INH), rifampicin (RIF), pyrazinamide,
and ethambutol was given to all patients for 2 months
followed by INH and RIF for 4 months. Clinical evalu-
ation, sputum microscopy, sputum culture and chest
radiography were performed [25]. A total of 249 patients
(modified intention-to-treat) completed the week 12
follow-up and 219 completed week 24 follow-up visit.
In the published TB trial, clinical assessments were
performed by the study doctor and were used to calcu-
late numerical clinical scores which was defined as a TB
score [25]. The TB score is an evaluation tool developed
by clinicians to quantify/determine changes in clinical
symptoms of the TB patients in an impartial and objective
manner. The TB score allocated points for self-reported
symptoms (cough, shortness of breath/dyspnea, chest
pain, haemoptysis, anorexia), and clinical signs assessed by
study doctors (fever, anemia (< 11 g/dl), tachycardia, aus-
cultatory findings). The TB score was determined at week
0–4, 6, 8, 10, 12 and 24.
For the present study, a sub-sample of 127 patients (32/
group) was selected for studying cytokine and chemokine
responses of PBMC for which adequate volume and
complete set of PBMC culture supernatants at 2 time
points (week 0 and 8) were available. In the vitD3
group, a complete set of 31 patients were only avail-
able. ER stress (18/group) and HBD1 (18/group)
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genes were studied using cDNA synthesized from
monocyte-derived-macrophages (MDM) of the TB
patients at week 0, 4 and 8. For studying autophagy
marker, MDM from 24 patients (6/group) were selected
with adequate number of cells available at 4 time points
(week 0, 4, 8 and 12).
Samples and cell culture supernatant
Peripheral blood mononuclear cells (PBMC) and plasma
were separated from whole blood by Ficoll-PaqueTM
PLUS (GE Healthcare, Uppsala, Sweden) density gradi-
ent centrifugation. PBMC were used directly following
isolation and were not stored in liquid nitrogen for fu-
ture use. After washing, PBMCs were suspended in cul-
ture medium and cultured for 2 days. Intracellular fluid
was collected after adding 0.1% saponin (Sigma-Aldrich,
Steinheim, Germany) and stored in ultra-low freezer for
analyses of cytokines (Fig. 1). Forty-eight hours of incu-
bation of PBMC without any stimulation allows partial
maturation of monocytes in the mixed cell culture (T
and B lymphocytes, NK cells, plasma cells and mono-
cytes). There is spontaneous and active release of
cytokines or antibodies directly from the immune cells
into the culture fluid (extracellular cytokines); reversible
permeabilization of PBMC by saponin additionally
allows excretion of intra-cellular cytokines into the
supernatant.
Five million PBMC were plated in 4-well culture plates
(NUNC, Roskilde, Denmark) for three days, after remov-
ing nonadherant cells the adherent MDMs were
harvested using a cell scraper, treated with RNAlater
(Qiagen GmbH, Hilden, Germany). Total RNA was
isolated from MDM using the RNeasy Mini Kit (Qiagen
GmbH). mRNA was reverse-transcribed and corre-
sponding cDNA was synthesized using the SuperScript
III First-Strand Synthesis System (Invitrogen Life Tech-
nologies, CA) with CFX96 real-time PCR detection
System (Bio-Rad, Hercules, CA, USA). The cDNA was
Fig. 1 The flow chart illustrates collection, processing and storage of different cell types from freshly isolated peripheral blood mononuclear cells
(PBMC), the time periods of cell culture and the various signature immune markers evaluated in these patients
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used for analysis of ER stress-related genes and HBD1
(Fig. 1).
Cytokines and chemokines
Multiplex kits (Bio-Rad) were used to analyze cytokines
and chemokines in the cell supernatants of PBMC
following manufacturer’s instructions in the Bioplex 200
system (Bio-Rad). Two types of kits were used, (i) the
27-plex kit contained a panel of 27 analytes: IL-1β,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10,
IL-12(p70), IL-13, IL-15, IL-17, CCL11 (eotaxin), FGF
basic, G-CSF, GM-CSF, IFN-γ, CXCL10 (IP-10), CCL2
(MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), PDGF-BB,
CCL5 (RANTES), TNF-α, and VEGF. (ii) The 17-plex
kit contained: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12(p70), IL-13, IL-17, G-CSF, GM-CSF, IFN-γ,
CCL2, CCL3 and TNF-α. For 75 patients 27-plex kit was
used (19/group; 18/vitD3 group), while for the rest of 52
patients (13/group) the 17-plex kit was utilized, there-
fore results for 8 analytes were not available for 52
patients.
Autophagy marker in macrophages
Autophagy is a physiological process; it is applied by
macrophages to control growth or elimination of intra-
cellular pathogens. LC3 is a classical marker and most
widely used for assessing the autophagy process LC3-I is
the cytosolic form of this protein. Upon activation of
autophagy, LC3-I is subsequently conjugated with phos-
phatidylethanolamine (PE) to generate LC3-II by a
ubiquitination-like enzymatic reaction. In contrast to the
cytoplasmic localization of LC3-I, LC3-II associates with
both the outer and inner membranes of the autophago-
some. This LC3-II protein looks like dots and is known
as ‘Puncta’. In a previous study, we have shown that
treatment of MDM with PBA increased the expression
of LC3 with simultaneous decrease in p62 protein
expression compared to untreated MDM [23]. Due to
the availability of limited number of cells from patients
at each time point, simultaneous staining of both LC3
and p62 was not feasible.
Freshly isolated PBMCs from TB patients [25] (above)
were cultured in culture medium for 3 days in 8-well
chamber slides (Nunc® Lab-Tek® Chamber Slide™ sys-
tem). After removal of non-adherent cells, adherent
MDM were infected with virulent Mtb strain, H37Rv
(Tuberculosis Research Center, Chennai, India) at a
multiplicity of infection (MOI) of 1:5 (1 macrophage to
5 bacilli (Mtb)) in culture media for 2 h without antibi-
otics in the BSL-3 facility. After washing to remove the
extracellular bacteria, the infected cells were fixed with
4% paraformaldehyde (Sigma-Aldrich) in phosphate
buffered saline and stored in − 80 °C until shipped to the
Laboratory in Karolinska Institute. The frozen slides
were brought to room temperature, and staining was
performed as mentioned earlier [23]. Quantification of
autophagy was performed based on the percentage of
the cells with LC3 punctate dots by ImageJ software
(National Institutes of Health, US).
Endoplasmic reticulum stress in MDM
As markers of ER stress, growth arrest and DNA dam-
age inducible protein 34 (GADD34) and spliced X-box
binding protein-1 (XBP1spl) mRNA were assessed in
MDM from TB patients (Fig. 1). The qPCR method was
performed as described previously [28] using the primer
pairs as follows: GADD34 forward primer 5’-ATGT
ATGGTGAGCGAGAGGC-3′, reverse primer 5’-GCAG
TGTCCTTATCAGAAGGC-3′; XBP1spl forward primer
5’-TGCTGAGTCCGCA-GCAGGTG-3′, reverse primer
5’-GCTGGCAGGCTCTGGGGAAG-3′. Relative mRNA
concentration of the reference gene ATP5B, (GeNorm,
PrimerDesign Ltd., Southampton, UK) was used to
calculate normalized expression. Each assay was run on
a CFX96 (Bio-Rad) in triplicates and arbitrary mRNA
concentrations were calculated by the Bio-Rad software,
using the relative standard curve method.
Human beta-defensin-1 (HBD1) in MDM
Expression of the gene encoding human β-defensin-1
was measured by qPCR using CFX96 (Bio-Rad) (Fig. 1).
The following primer sequences were used for quantifi-
cation of HBD1. Sense primer: 5′-ATGGCCTCA-GGTG
GTAACTTTC-3′; antisense primer: 5′-CACTTGGCC
TTCCCTCTGT-AAC-3′. Relative quantification method
was used to the housekeeping RNA18S/18S rRNA (18S
rRNA–housekeeping gene kit, Applied Biosystems,
Foster. City, USA). Results were expressed as relative
gene expression and the 2–ΔΔCT method or fold
changes. ΔCt values were calculated by subtracting 18 s
rRNA Ct values from HBD1 Ct values of the same sam-
ple. Thereafter, ΔΔCt was obtained by subtracting aver-
age placebo week 0 ΔCt value from all ΔCt values.
Finally, HBD1 relative gene expression was calculated by
the formula, 2-ΔΔCt [29].
Statistical analysis
Distribution of different adjunct treatments (Placebo, PBA,
vitD3 and PBA+ vitD3) were calculated based on demo-
graphic characteristics (age, gender, history of contact,
body weight, vitamin D status). Cytokine and chemokine
data was log transformed due to non-normal distribution,
and a simple interpretation of the beta-coefficient (average
changes in outcome (concentration of cytokines, chemo-
kines, number (%) of autophagy marker LC3 etc.) associ-
ated with change in treatment group with respect to
placebo). Cytokine and chemokine responses of each of
the 127 patients were studied at 2 time points, at week 0
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and week 8. Wilcoxon Signed Ranks test was performed to
evaluate the changes in cytokine and chemokine concen-
trations within each treatment group. To assess the treat-
ment effects on changes in outcome variables (cytokine/
chemokine concentrations and autophagy marker LC3+
cell counts) over time, generalized estimating equation
(GEE) model was performed considering exchangeable
correlation matrix. Each cytokine, chemokine and LC3+
cell counts (autophagy marker) was individually analyzed
using the GEE model allowing repeated measures per
patient to reduce longitudinal multicollinearity. The treat-
ment effects were adjusted by covariates that influence the
model by at least 5% (age, sex, duration of symptoms,
history of contact with active TB cases and time at week 0
and week 8 (week 4 and 12 were considered where applic-
able)). The interaction between the treatment groups and
time were also minimized. An ANCOVA model was
applied to see the mean difference of gadd34, xbp1spl and
HBD1 among different treatment groups. In both cases of
GEE and ANCOVA, a p-value of < 0.05 was considered
significant. All the data were analyzed by using the Statis-
tical package for the Social Science (SPSS) for Windows
(version 20; Armonk, NY: IBM SPSS corp.; 2011) and
Stata/IC, version13 (Stata Corp, Texas, USA).
Results
Patients and clinical scores
Of total 249 patients, samples from 127 patients were
included in the present study where mean age of the
patients was 27.25 ± 8.37 years and female male ratio
was 1:1.86 (35:65). The patient groups in the present
study did not differ significantly in demographic and
baseline characteristics amongst themselves (Table 1) or
from the primary patient cohort who were not included
in the present study (Additional file 1: Table S1).
Longitudinal change in TB scores as analyzed by GEE
showed a significant decline over time (week 0, 4, 8 and
12) in the PBA group compared to placebo (Additional
file 1: Table S2) in the present cohort (n = 127). A similar
reduction in TB scores was obtained in the PBA group
compared to placebo in the parent cohort of 249
patients [25]. Significantly higher percentages of patients
in the PBA + vitD3 and vitD3 groups became sputum
culture negative at week 4 compared to placebo though no
difference was obtained with sputum smear conversion.
Cytokines and chemokines
Concentrations of cytokines IL-2, IL-5, IL-13 and IL-15
in PBMC supernatants were low or below detection limit
in most patients. The other cytokines and chemokines
showed a wide range of concentrations in all the super-
natants measured. Concentrations of TNF-α, IL-17 (p =
0.05) and CCL11 (eotaxin) (p = 0.01) declined signifi-
cantly from week 0 to week 8 in the PBA group. In the
PBA + vitD3 group, FGF-basic and PDGF-β reduced in
concentrations after 8 weeks from week 0 (p = 0.01)
(Additional file 1: Table S3). Other groups did not show
any significant reduction in cytokine/chemokine concen-
trations with time.
Analysis by GEE method exhibited a significant decline
in TNF-α (β = − 0.34, 95% CI = − 0.68, − 0.003, p = 0.04)
concentrations from week 0 to week-8 in the PBA group
compared to placebo (Table 2). A significant reduction
in the concentrations of the chemokines CCL11 (β = −
0.19, 95% CI = − 0.36, − 0.03, p = 0.02) and CCL5
(RANTES) (β = − 0.08, 95% CI = − 0.16, 0.002, p = 0.05)
Table 1 Demographic characteristics of the study participants
Characteristics Placebo (n = 32) PBA (n = 32) vitD3 (n = 31) PBA + vitD3 (n = 32)
Age, years 27.38 ± 8.65 27.72 ± 7.25 25.42 ± 8.15 27.16 ± 8.38
Males 20 (62.50%) 22 (25.90%) 21 (67.70%) 22 (68.80%)
History of contacts 10 (31.30%) 11 (34.40%) 6 (19.40%) 8 (25.00%)
BCG given 22 (68.8%) 19 (59.4%) 26 (83.90%) 23 (71.90%)
Weight, kg 44.75 ± 8.20 45.74 ± 8.91 42.91 ± 8.70 44.00 ± 7.89
Duration of illness, days 48.91 ± 25.42 50.63 ± 21.80 58.39 ± 26.81 52.47 ± 27.58
Vitamin D status
Deficient, < 30 nmol/L 18 (56%) 23 (71%) 21 (67%) 16 (50%)
Insufficient, 30–50 nmol/L 10 (31.30%) 6 (18.8%) 5 (16.10%) 12 (37.50%)
Sufficient, > 50 nmol/L 4 (12.50%) 3 (9.4%) 5 (16.10%) 4 (12.50%)
Baseline clinical score (25) 6.47 ± 0.86 6.45 ± 1.09 6.27 ± 1.01 6.39 ± 0.96
Baseline sputum smear
< 3 acid-fast bacilli 17 (43.10%) 17 (43.10%) 16 (51.60%) 18 (56.20%)
> 3 acid-fast bacilli 15 (46.90%) 15 (46.90%) 15 (48.40%) 14 (43.80%)
Data is presented as mean ± standard deviation or number with percentage in parentheses
Abbreviations: BCG Bacillus Calmette–Guérin
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was observed in the PBA group, while CCL11 (β = −
0.17, 95% CI = − 0.34, − 0.001, p = 0.04), CXCL10 (IP-10)
(β = − 0.38, 95% CI = − 0.77, 0.003, p = 0.05) and PDGF-β
(β = − 0.16, 95% CI = − 0.31, 0.002, p = 0.05) declined sig-
nificantly in the vitD3 group (Table 2). However, no dif-
ferences in chemokine concentrations were noted in the
PBA + vitD3 group compared to placebo. The results
demonstrated that 8 weeks’ adjunct therapy with oral
PBA or vitD3 effectively decreased expression of
mononuclear cell-derived inflammatory cytokines and
chemokines thereby reflecting reduced inflammatory
responses in TB patients.
Autophagy marker in ex vivo infected macrophages
Confocal microscopic analysis revealed the activation of
autophagy process in macrophages measured by the
presence of LC3 positive puncta in MDM. LC3 puncta
structures in ex vivo infected MDM showed highest
Table 2 Longitudinal change (week 0 and 8) in inflammatory cytokines in treatment groups compared to placebo
Crude Adjusteda
β(95% CI) p-value β(95% CI) p-value
TNF-α
PBA (n = 32) − 0.17 (− 0.42, 0.09) 0.20 − 0.34 (− 0.68, − 0.003) 0.04
vitD3 (n = 31) − 0.16 (− 0.41, 0.10) 0.23 − 0.22 (− 0.57, 0.13) 0.22
PBA + vitD3 (n = 32) −0.13 (− 0.38, 0.13) 0.32 − 0.03 (− 0.37, 0.31) 0.85
IL-8
PBA (n = 32) −0.29 (− 0.68, 0.09) 0.13 − 0.33 (− 0.71, 0.05) 0.08
vitD3 (n = 31) − 0.11 (− 0.50, 0.28) 0.57 −0.09 (− 0.49, 0.30) 0.63
PBA + vitD3 (n = 32) −0.17 (− 0.55, 0.22) 0.39 −0.18 (− 0.55, 0.20) 0.36
GM-CSF
PBA (n = 32) −0.13 (− 0.38, 0.11) 0.28 − 0.27 (− 0.56, 0.01) 0.06
vitD3 (n = 31) − 0.19 (− 0.44, 0.05) 0.12 −0.19 (− 0.49, 0.10) 0.20
PBA + vitD3 (n = 32) 0.08 (−0.17, 0.32) 0.54 0.06 (−0.23, 0.35) 0.69
IL-4
PBA (n = 32) −0.10 (− 0.23, 0.03) 0.14 − 0.14 (− 0.31, 0.01) 0.08
vitD3 (n = 31) − 0.08 (− 0.21, 0.06) 0.26 −0.11 (− 0.27, 0.06) 0.20
PBA + vitD3 (n = 32) −0.06 (− 0.20, 0.07) 0.35 −0.05 (− 0.22, 0.11) 0.52
CCL11 (eotaxin)
PBA (n = 20) −0.03 (− 0.17, 0.10) 0.63 − 0.19 (− 0.36, − 0.03) 0.02
vitD3 (n = 17) −0.11 (− 0.26, 0.03) 0.11 −0.17 (− 0.34, − 0.001) 0.04
PBA + vitD3 (n = 19) −0.04 (− 0.18, 0.10) 0.59 −0.07 (− 0.23, 0.10) 0.44
CCL5 (RANTES)
PBA (n = 20) −0.07 (− 0.13, − 0.001) 0.04 −0.08 (− 0.16, 0.002) 0.05
vitD3 (n = 17) −0.05 (− 0.12, 0.01) 0.11 −0.06 (− 0.15, 0.02) 0.14
PBA + vitD3 (n = 19) −0.04 (− 0.10, 0.03) 0.27 −0.06 (− 0.14, 0.03) 0.18
CXCL10 (IP-10)
PBA (n = 20) −0.11 (− 0.41, 0.18) 0.45 − 0.13 (− 0.51, 0.24) 0.47
vitD3 (n = 17) − 0.25 (− 0.57, 0.06) 0.10 −0.38 (− 0.77, 0.003) 0.05
PBA + vitD3 (n = 19) −0.15 (− 0.46, 0.15) 0.32 −0.16 (− 0.54, 0.21) 0.39
PDGF-BB
PBA (n = 20) −0.03 (− 0.18, 0.12) 0.71 0.01 (− 0.15, 0.16) 0.92
vitD3 (n = 17) −0.16 (− 0.32, − 0.003) 0.04 −0.16 (− 0.31, 0.002) 0.05
PBA + vitD3 (n = 19) −0.12 (− 0.28, 0.03) 0.10 −0.12 (− 0.27, 0.03) 0.12
Data is presented as beta coefficient with 95% confidence intervals in parentheses
Abbreviations: CI confidence interval, PBA phenylbutyrate, vitD3 vitamin D3, TNF-α tumor necrosis factor-alpha, IL interleukin, GM-CSF granulocyte-macrophage-
colony stimulating factor, PDGF-BB platelet-derived growth factor-BB
aAdjusted for age, sex, duration of treatment, history of contact with active TB cases.
Statistical analysis was performed using generalized estimating equation (GEE) model. P-value of < 0.05 is significant
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percentage of cells with LC3-positive puncta in PBA +
vitD3 group at week 8 (Fig. 2a).
There was a basal number of LC3 expressing cells (4.3
± 2.4) among the uninfected MDM in all the treatment
arms of patients that did not change with different therap-
ies or over the duration of the study period (Fig. 2b). In all
groups a gradual increase in percentage of LC3-expressing
H37Rv-infected MDM from week 0 up to week 12 was
noted, indicating that the capacity of MDM to undergo
autophagy increased with time during clinical recovery
(Fig. 2a and b). Analysis by GEE model showed that mean
changes of LC3-expressing macrophage percentage in
PBA (β = 8.26, 95% CI = 3.61, 12.9, p < 0.001), vitD3 (β =
4.73, 95% CI = 0.28, 9.19, p = 0.037) and PBA+ vitD3 (β =
10.47, 95% CI = 5.33, 15.6, p < 0.001) were significantly
higher compared to placebo (Fig. 3). Hence, oral adjunct
therapy with PBA, vitD3 and the combined dose had a
positive impact on priming for induction of autophagy in
ex vivo-infected macrophages from TB patients that per-
sisted up to additional 4 weeks after the adjunct therapy
was completed.
Endoplasmic reticulum stress markers and HBD1 in
macrophages
When MDM from TB patients were examined for ER
stress genes, there were few time points where gene
Fig. 2 a Expression of LC3+ macrophages in TB patients after adjunct therapy with PBA and/or vitD3 and simultaneously under treatment with anti-TB
drugs. MDMs derived from the patients were infected with the virulent strain of Mycobacterium tuberculosis H37Rv for 2 h. The cells were fixed and
stained with DAPI to visualize the nuclei (blue), and with anti-LC3, followed by the addition of Alexafluor 488-conjugated goat anti-mouse IgG (green
color). One representative immunofluorescence image out of 6 independent replicates are shown; scale bars: 10 μm. b Percentage of LC3 expressing
cells among uninfected and Mtb-infected monocyte-derived-macrophages (MDM) in the four treatment arms
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expression was below detection limit for GADD34 or
XBP1spl. These were considered as missing values in
ANCOVA. All groups revealed a decline in expression of
GADD34 transcripts from week 0 to week 8. However,
sex and age-adjusted ANCOVA analysis did not reveal
any significant difference in the expression of GADD34
transcripts between the treatment groups and placebo
(Fig. 4a). Interestingly, a significant reduction in the ex-
pression of XBP1spl transcripts was found at week 8 in
PBA (p = 0.036) and vitD3 (p = 0.008) groups compared to
placebo but not in PBA + vitD3 (p = 0.12) group (Fig. 4b).
Both PBA and vitamin D3 are known for their role in re-
ducing ER stress in cells (26 or 27) [30]. Host directed
therapy with PBA or vitamin D3 could individually
dampen the ER stress in MDM, although the combined
intervention did not reach a statistically significant level.
In addition to studying expression of cathelicidin
LL-37 in MDM in the original study [25], we further
assessed effect of PBA and/or vitD3 on induction of
HBD1 in MDMs. The expression of HBD1 transcripts
(2–ΔΔCT) in different intervention groups did not change
significantly with time. Furthermore, the fold change in
HBD1 transcripts did not exhibit any difference over
time in any of the intervention groups compared to pla-
cebo (Table 3).
Discussion
It is important to evaluate the role of immune-modulatory
agents as host directed therapy in the treatment of TB that
can improve efficacy of therapy, reduce or prevent detri-
mental outcomes of toxic drugs and improve patient com-
pliance. Our interest in using PBA and/or vitD3 as HDT
in the treatment of TB was based on their diverse roles in
modifying the host defense system. Our findings showed
that adjunctive treatment with PBA or vitD3 over 8 weeks’
time reduced concentration of cytokines/chemokines and
endoplasmic reticulum stress in parallel to clinical recov-
ery. All three adjunctive therapies increased frequency of
autophagy in macrophages compared to placebo.
TB is a chronic infectious disease with a spectrum of
symptoms and presentations, wherein cytokines and
chemokines play important roles in manipulation of the
immune responses, containment of Mtb, pathogenesis
and disease manifestations. Various studies have com-
pared serum cytokine/chemokine profiles of patients
with different clinical presentations of TB, to establish
the expression levels as early surrogate biomarkers of
therapeutic responses, bacteriological confirmation of
TB and sputum culture conversion [31–33]. We mea-
sured cytokines and chemokines in culture supernatants
of PBMC instead of serum or plasma, and the findings
were similar to previous studies, showing marked
decline of serum cytokine/chemokine concentrations at
different treatment stages [14, 33–37]. Particularly we
found that compared to conventional anti-TB treatment
in the placebo group, cytokine/chemokine reduction was
greater in the PBA or vitD3 groups that occurred in par-
allel to clinical recovery [25] (reduced TB score), sug-
gesting a role of PBA and vitD3 in dampening of
inflammatory responses.
Mycobacterial infection has been shown to induce ER
stress and damage ER. Cells deal with ER stress by acti-
vation of the unfolded protein response (UPR), but
chronic activation of these pathways can eventually
result in apoptosis and lung injury [18, 38–40]. Several
biomarkers of ER stress have been used in various stud-
ies by assessing activation of the UPR; spliced X-box
binding protein-1 (XBP1spl) mRNA has been shown to
Fig. 3 Generalized estimating equation (GEE) model was used to estimate the effect of adjunct therapy on LC3-expressing macrophages over
time (week 0, 4, 8 and 12). β coefficient values are shown for three intervention groups (PBA, vitD3 and PBA + vitD3) compared to placebo.
Arrowhead points represent the adjusted beta (β) coefficient values and vertical lines define 95% confidence intervals (CI). The analysis showed
that mean % changes of LC3-expressing macrophage in PBA (β = 8.26; p < 0.001), vitD3 (β = 4.73; p = 0.037) and PBA+ vitD3 (β = 10.47; p < 0.001)
were significantly higher compared to the placebo group
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be a reliable marker in revealing dose-dependent
changes in the transcript level of this gene [28]. Myco-
bacterial secreted antigens such as ESAT-6 has been
shown to increase XBP1spl as well as other ER stress
genes in epithelial cell lines [38]. Toll-like receptor acti-
vation was also shown to increase splicing of the tran-
scription factor XBP1 in the absence of other signs of
activation of the UPR, and this was found to regulate
innate immune responses in macrophages [41]. PBA is a
classic ER stress inhibitor; it is a chemical chaperone
that improves ER folding capacity and trafficking of
mutant proteins out of the ER, stabilization of protein
conformation and thereby reduces accumulation of
misfolded proteins in ER lumen. In cell lines, experimen-
tal models and tissue samples, PBA has been shown to
reduce expression of GRP-78, CHOP and other
UPR-related markers such as ATF6, XBP1 and phos-
phorylation of eIF2α [27, 42–44]. Vitamin D is also con-
sidered a natural ER stress reliever [30, 45].
Down-regulation of GADD34 transcripts after 8 weeks
of therapy was evident in all 4 arms, however
down-regulation of spliced XBP1 was evident only in
PBA and vitD3 arms compared to placebo. Thus, in vivo
effect of PBA and vitD3 adjunct treatments was demon-
strated in diminishing ER stress in MDM during TB
infection that may have a role in improving clinical
Table 3 Longitudinal change (week 0, 4, 8) in HBD1 in the treatment groups compared to Placebo (n = 18)
Crude Adjusteda
HBD1 β(95% CI) p-value β(95% CI) p-value
PBA (n = 18) 0.26 (−0.10, 0.62) 0.15 0.31 (−0.06, 0.67) 0.10
vitD3 (n = 18) −0.05 (− 0.40, 0.29) 0.76 0.04 (− 0.31, 0.40) 0.81
PBA + vitD3 (n = 18) 0.21 (−0.15, 0.56) 0.25 0.28 (−0.09, 0.66) 0.14
Data is presented as beta coefficient with 95% confidence intervals in parentheses
Abbreviations: CI confidence interval, HBD1 human beta-defenisn-1
aAdjusted for age, sex, duration of treatment, history of contact with active TB cases, time and the interaction between the treatment groups and time.
Statistical analysis was performed using generalized estimating equation (GEE) model. P-value of < 0.05 is significant
Fig. 4 Real-time RT-PCR assays of GADD34 and XBP1spl mRNAs from monocyte-derived-macrophages from TB patients receiving adjunct therapy
with PBA and/or vitD3 or placebo (18/group) at week 0, week 4 and 8 after therapy. Data are normalized expression of GAD34 (a) and XBP1spl (b)
mRNAs presented as means ± standard deviation. The results showed that PBA and vitD3 groups showed a significant reduction in expression of
ER stress gene spliced XBP1 mRNA at week 8 compared to placebo
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outcome. Moreover, diminished inflammatory cytokine
responses as we have shown here may be linked to sup-
pression of ER stress [46, 47].
Autophagy is an important physiological process that
is applied by macrophages to control and eliminate
intracellular pathogens. We have earlier demonstrated in
a mechanistic study that PBA, active vitD3 separately
and in combination induced autophagy in macrophages
from healthy donors when infected in vitro with Mtb
[23], increased the intracellular killing of Mtb compared
to untreated MDM and induced LL-37 in cell superna-
tants of macrophages and lymphocytes after oral inges-
tion by healthy adults [22]. The novel activity of PBA as
an inducer of autophagy was LL-37-dependent. We fur-
ther showed in the present study that, all three adjunct-
ive therapies (PBA, vitD3 and PBA + vitD3) in the
clinical trial [25] promoted autophagy in ex vivo infected
macrophages from the patients, indicating that the
inducers can prime the macrophages for autophagy
response. Moreover, the autophagy process occurred in
parallel to induction of LL-37 in macrophage/PBMC
[25], continuing up to an additional week after the
adjunct therapy was completed. MDM-mediated elimin-
ation of Mtb in the vitamin D and PBA + vitamin D3
arms in the trial thus strongly suggest a role of the
autophagy process in the eradication. Autophagy also
plays a housekeeping role in removing misfolded,
unfolded or aggregated proteins and clearing damaged
organelles, such as ER and mitochondria. In view of the
involvement of the UPR in activating autophagy, it is
interesting to note that whereas treatment increased
autophagy, it appeared to decrease activation of the UPR
to ER stress. This suggests that mechanisms distinct from
the UPR are involved in the observed treatment-induced
autophagy.
Human beta defensin-1 (HBD1) is produced constitu-
tively by all human epithelia and some immune cells.
Monocyte-derived-macrophages and -dendritic cells
both express HBD1 mRNA, showing increased expres-
sion after activation with IFN-γ and/or lipopolysacchar-
ide in a dose- and time-dependent fashion [48]. When
expression of HBD1 transcripts was studied in MDMs
from the patients we did not observe any increase or
down-regulation of the peptide in the treatment groups
compared to placebo during the course of TB disease.
Thus, PBA or vitD3 did not seem to have any modulat-
ing effect on HBD1 expression in peripheral MDM as
seen with LL-37 [25].
One of the limitations of this study was the small size
used per treatment group for evaluation of ER stress
genes and HBD1 genes. The expression of transcripts
was studied only in macrophages, not other cells in
PBMC. This was done because of unavailability of
adequate number of matched/paired samples from
different time points and suboptimum concentrations of
specimens remaining from the clinical trial. Our analysis
of activation of the UPR was restricted to measurement
of GADD34 and XBP1spl because of limitations in the
availability of RNA, and therefore other UPR markers
(including protein markers) should be assessed in future
studies. Only one autophagy marker LC3 was used
instead of a combination of markers such as ATG 5 and
Beclin-1; however, our earlier studies showed the LC3
marker as reliable for assessment of autophagy in mac-
rophages [23]. The combined adjunct therapy of PBA
and vitD3 did not exhibit any effect on cytokines/chemo-
kines or ER stress reduction in TB patients and require
further investigations. Notably, the combined treatment
with PBA and vitD3 of the patients exhibited the fastest
sputum culture conversion [25]. Another limitation was
that we measured cytokines and chemokines in
saponin-treated cell culture fluid instead of serum or
plasma as traditionally done [10–14, 31–33]. Measurement
of cytokines in the serum does not accurately reflect active
secretion of cytokines due to an ongoing infection; more-
over it is affected by clearance from the circulation. Our hy-
pothesis is that the PBMC from TB patients are in vivo
activated and they do not require ex-vivo stimulation; re-
lease of cytokines/chemokines from unstimulated cells into
the culture supernatant indicate active secretion and thus
are more relevant to the ongoing disease process. However,
use of saponin allowed excretion of intra-cellular cytokines
into the culture supernatant which was not a spontaneous
release of cytokines.
Conclusions
demonstration of clinically beneficial immunomodula-
tion that occur in parallel to improved treatment out-
comes suggest that use of repurposed agents such as
Phenylbutyrate and vitamin D3 can be a valuable strategy
in HDT against drug-sensitive TB. The toxicities and
poor treatment outcomes of current therapies against
MDR-TB necessitate newer approaches to improve the
management and control of MDR-TB. Development of
host-directed therapies integrated with Mtb-targeted
chemotherapy provides a complicated challenge because
temporal events of infection and host immunity may
play a critical role in determining HDT efficacy. Thus,
the therapeutic potential of PBA and vitD3 HDT against
multidrug resistant TB warrants urgent clinical evalu-
ation in well-designed multi-center clinical trials in en-
demic settings.
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